Biotie updates outlook - completion of annual impairment

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Biotie updates outlook - completion of annual impairment review

BIOTIE THERAPIES CORP.     STOCK EXCHANGE RELEASE                  27 February 2015 at 8.40 a.m. Biotie updates outlook - completion of annual impairment review Biotie has completed its annual impairment review of intangible assets and goodwill. This has resulted in a non-cash impairment charge being recognized in the consolidated statement of comprehensive income for the year-ended 31 December 2014 in respect of nepicastat (SYN117) and SYN120. The carrying value of both tozadenant (SYN115) and goodwill was fully supported by the review. On 30 January 2015, Biotie announced top-line results from a Phase 2 clinical study with nepicastat in cocaine-dependent patients. When compared to placebo, nepicastat did not meet the primary efficacy endpoint of an increased proportion of subjects remaining abstinent from cocaine during the last two weeks of the treatment period. As a result, the carrying value of nepicastat has been fully impaired on 31 December 2014. This has resulted in a non-cash impairment charge of EUR 11.1 million, which will be recognized in the consolidated statement of comprehensive income in Q4 2014. The impairment review for SYN120 has been performed using Parkinson's disease dementia as the indication, following the start of recruitment in the Phase 2 study in Q4 2014. This has resulted in an impairment charge of EUR 16.5 million being recognized in the consolidated statement of comprehensive income in Q4 2014. Should the development plans change, including for example if the previously planned Alzheimer's disease study could be funded, then this may result in an increase in the value of the asset to a maximum of the impaired amount. Turku, 27 February 2015 Biotie Therapies Corp. Timo Veromaa President and CEO Further information: For further information, please contact: Virve Nurmi, Investor Relations Manager tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com Distribution: NASDAQ OMX Helsinki Ltd Main media www.biotie.com About Biotie Biotie is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner Lundbeck. The current development products include tozadenant for Parkinson's disease, which is transitioning into Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver. [HUG#1897890]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celebrating Leaders Advancing Type 1 Diabetes Research

Updated Category News Views 62

Honoring Trailblazers in Type 1 Diabetes Research It's not every day that we get to shine a spotlight on the unsung heroes in the field of Type 1 Diabetes (T1D) research. Today, we pause to celebrate those who are doing the heavy lifting to make the lives of millions better. Breakthrough T1D, the name says it all, presented its prestigious awards to four titans of...

Continue Reading
Hitachi's Smart Energy Move: AI Capacity Boost Unveiled

Updated Category News Views 95

Tackling Energy Challenges in Data Centers Data centers are struggling to keep up with the surging demand for computing power fueled by artificial intelligence, but Hitachi Vantara is flipping the script on how to handle it. Over in the Netherlands, they're working some serious tech magic by deploying a groundbreaking method to wrangle energy use and boost AI capability...

Continue Reading
OriginPoint Boosts Growth with $200M Lender Team

Updated Category News Views 22

Mortgage Powerhouses Join Forces with OriginPoint It's not every day you see a $200 million mortgage team making a beeline for new pastures, but today's landscape seems ripe for such moves. Enter the We Fund LA team, led by mortgage veterans Daniel Arias and Ron Sequeira, as they align with OriginPoint Mortgage to scale new heights in Southern California. This isn't just...

Continue Reading
Elbit Systems Poised for Q3 2026 Earnings Reveal

Updated Category News Views 53

Elbit Systems: A Strategic Player in Defense Here's what's going on with Elbit Systems Ltd. (NASDAQ:ESLT), the Israeli defense heavy hitter. They're gearing up to spill the beans on their Q3 financial results this November 17th. And for those of us keeping an eye on how defense contractors are adapting to today's chaotic geopolitical climate, this is a date you don't want...

Continue Reading
Nevada King's Gold Drilling Could Yield Big Returns

Updated Category News Views 64

Unlocking Gold's Potential: A First Look Another day, another drill result, and this time it's Nevada King Gold Corp. (TSXV: NKG) (OTCQX: NKGFF) dropping the headlines. They've been playing in the dirt at their Atlanta Gold Mine Project in Nevada, unveiling numbers that might shake some of you out of your chairs. Peeking Into East Ridge and Silver Park Let's talk turkey,...

Continue Reading
Multiplier's Data Signals Global Hiring Evolution

Updated Category News Views 0

Shaking Up the Global Hiring Playbook You think you know how hiring works globally? Think again. Based on data from a whopping 38,000 cross-border hires, Multiplier's latest Talent Trends has spilled some hot new beans on how companies are rethinking their talent acquisition strategies. This isn’t just some thumb-twiddling speculation either—it’s grounded in real...

Continue Reading
Venezuelan Crude Hits Texas: NABEP's Bold Move

Updated Category News Views 90

Venezuelan Crude Docking in Texas Signals New Energy Dynamics Batten down the hatches, 'cause NABEP's Venezuelan crude has made a splashy arrival in Texas. We're talking 1 million barrels, folks, the first of its kind under a fresh U.S. deal. This ain't your grandpa's oil shipment from the Middle East that takes forever to get here—nope, this crude made a pit stop in...

Continue Reading
Backroads Invites Families: Adventures Boost Bookings by 20%

Updated Category News Views 118

Rediscovering Family Time Through Adventure When was the last time a winter vacation got you this fired up? Backroads, the trailblazer in active getaways, is bucking the trend of typical holiday madness. Families are ditching the usual gift-giving grind for something way more memorable: experiences that blend action with bonding across generations. Big Numbers, Big...

Continue Reading
Etisalat Surges: Net Profit Soars 46% Amid Growth

Updated Category News Views 91

Etisalat's Stellar Performance: A Deeper Dive When a company like Etisalat drops news of a whopping 46% increase in net profit year-over-year, you sit up and pay attention. Those numbers aren’t just a flash in the pan; they're the result of some serious strategic maneuvers and ripe market conditions. Etisalat isn't resting on its laurels, and their latest financials...

Continue Reading
mainelove Rides High With Double Gold and Growth

Updated Category News Views 69

mainelove Shakes Up the Water Scene Well ain't that a splash? mainelove, the Maine-sourced water outfit, just snagged itself some shiny Double Gold hardware at the 2026 Water Choice Awards. Makes you raise a glass—or a can, I suppose—to see a local brand licking its chops over a win like this. It's not every day you hear a water company nailing it across state lines,...

Continue Reading
>